Volume 22, Issue 1 (Iranian South Medical Journal 2019)                   Iran South Med J 2019, 22(1): 1-15 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mirzazadeh E, Khezri S, Abtahi Froushani S M. Effects of Quercetin on Improving the Damage Caused by Free Radicals in the Rat Models of Multiple Sclerosis. Iran South Med J 2019; 22 (1) :1-15
URL: http://ismj.bpums.ac.ir/article-1-1044-en.html
1- Department of Biology, School of Sciences, Urmia University, Urmia, Iran
2- Department of Biology, School of Sciences, Urmia University, Urmia, Iran , sh.khezri@urmia.ac.ir
3- Department of Microbiology, School of Veterinary, Urmia University, Urmia, Iran
Abstract:   (3788 Views)
Background: Medicinal herbs have been used for managing various diseases for many years. Quercetin is a member of flavonoid family with antioxidant and anti-inflammatory properties. This study aimed to
investigate the beneficial potential of quercetin in ameliorating experimental autoimmune encephalomyelitis (EAE).
Materials and Methods: In this experimental study, EAE was induced in male Wistar rats by guinea pig spinal cord homogenate and complete Freund’s adjuvant. Then, the rats were allocated into three equal groups (n=10). Quercetin administration (10 mg/kg daily) initiated on day 12 post-immunization, when the rats developed a disability score. The brains and blood samples were collected on day 36 and used for next experiments.
Results: Quercetin therapy led to a better outcome in EAE rats compared to EAE rat without treatment. Myeloperoxidase activity and nitric oxide levels in the sera and the lipid peroxidation level in the brain tissues of EAE rats were significantly increased in EAE rats compared to normal control rats (P<0.05). Serum level of uric acid insignificantly decreased in EAE rats compared to normal control rats (P<0.05).
Conclusion: It appears that quercetin is a promising strategy to be added to the treatment protocol of MS patients.
Full-Text [PDF 965 kb]   (1378 Downloads)    
Type of Study: Original | Subject: Pharmacology
Received: 2017/12/26 | Accepted: 2018/12/2 | Published: 2019/04/7

1. Nakahara J, Maeda M, Aiso S, et al. Current concepts in Multiple Sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol 2012; 42(1): 26-34. [DOI:10.1007/s12016-011-8287-6]
2. Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg 2010; 112(5): 365-85.Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg 2010; 112(5): 365-85. 3.Goldenberg MM. Multiple sclerosis review. PT 2012; 37(3): 175-84. [DOI:10.1016/j.clineuro.2010.03.010]
3. Goldenberg MM. Multiple sclerosis review. PT 2012; 37(3): 175-84. [PubMed]
4. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol 2012; 142(1):2-8. [DOI:10.1016/j.clim.2011.03.004]
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996; 46(4): 907-11. [DOI:10.1212/WNL.46.4.907]
6. Zirak Marangalu H, Khezri S, Abtahi M. Improvement in the function of rat peripheral blood monocytes following oral administration of curcumin. JSSU 2017; 25(3): 171-82. [Article]
7. Shahidi F. Extraction and analysis of phenolics in food. J Chromatogr A 2004; 1054: 95-111. [DOI:10.1016/S0021-9673(04)01409-8]
8. Emamat M H, Mirmiran P, Hekmatdoost A. Quercetin flavonoid and non-alcoholic fatty liver disease. Yafte 2016; 18(1): 90-100. [Article]
9. Li X, Wang R, Zhou N, et al. Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in aNSFLD cell model. Biomed Rep 2013; 1(1): 71-6. [DOI:10.3892/br.2012.27]
10. Pekkarinen SS, Heinonen IM, Hopia AI. Flavonoids quercetin, myricetin, kaempferol and (+)-catechin as antioxidants in methyl linoleate. J Sci Food Agricul 1999; 79: 499-506. https://doi.org/10.1002/(SICI)1097-0010(19990315)79:4<499::AID-JSFA204>3.0.CO;2-U [DOI:10.1002/(SICI)1097-0010(19990315)79:43.0.CO;2-U]
11. Shahidi F, Naczk M. Phenolics in food and nutraceuticals. 2nd ed. United States: CRC Press, 2003, 1- 576. [Link]
12. Zaveri NT. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 2006; 78(18): 2073-80. [DOI:10.1016/j.lfs.2005.12.006]
13. Zhu M, Huang Y, Wang Y, et al. Comparison of (poly)phenolic compounds and antioxidant properties of pomace extracts from kiwi and grape juice. Food Chem 2019; 15(271): 425-32. [DOI:10.1016/j.foodchem.2018.07.151]
14. Morvaridi A, Delirezh N, Hobbenaghi R, et al. The effects of All-Trans Retinoic Acid on clinical symptoms, nitric oxide levels and total antioxidant capacity of plasma in mouse model of multiple sclerosis. RJMS 2013; 20(108): 11-9. [Article]
15. Abtahi Froushani SM, Delirezh N, Hobbenaghi R, et al. Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis. Immunol Invest 2014; 43(1): 54-68. [DOI:10.3109/08820139.2013.825269]
16. Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 2008; 58(4): 625-31. [DOI:10.1016/j.jaad.2007.12.035]
17. Qureshi M, Al-Suhaimi EA, Wahid F, et al. Therapeutic potential of curcumin for multiple sclerosis. Neurol Sci 2017; 39(2): 207-14. [DOI:10.1007/s10072-017-3149-5]
18. Alrawaiq NS, Abdullah A. A review of flavonoid quercetin: metabolism, bioactivity and antioxidant properties. Int J PharmTech Res 2014; 6(3): 933-41.
19. Orsolic N, Knezevic AH, Sver L, et al. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. J Ethnopharmacol 2004; 94(2-3): 307-15. [DOI:10.1016/j.jep.2004.06.006]
20. Manjeet KR, Ghosh B. Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-alpha production in murine macrophages. Int J Immunopharmocol 1999; 21(7): 435-43. [DOI:10.1016/S0192-0561(99)00024-7]
21. Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm. Inflamm Allergy Drug Targets 2010; 9(4): 263-85. [DOI:10.2174/187152810793358741]
22. Huang RY, Yu YL, Cheng WC, et al. Immunosuppressive effect of quercetin on dendritic cell activiation and function. J Immunol 2010; 184(12): 6815-21. [DOI:10.4049/jimmunol.0903991]
23. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25(6): 1102-11. [DOI:10.1161/01.ATV.0000163262.83456.6d]
24. Daugherty A, Dunn JL, Rateri DL, et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94(1): 437-44. [DOI:10.1172/JCI117342]
25. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999; 103(11): 1547-60. [DOI:10.1172/JCI5549]
26. McColl SR, Staykova MA, Wozniak A, et al. Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J Immunol 1998; 161(11): 6421-6.
27. Steinbach K, Piedavent M, Bauer S, et al. Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs. J Immunol 2013; 191: 4531-39. [DOI:10.4049/jimmunol.1202613]
28. YJ Kim, JM Shin, SH Shin, et al. palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol ameliorates arthritic joints through reducing neutrophil infiltration mediated by IL-6/STAT3 and MIP-2 activation. Oncotarget 2017; 8(57): 96636-48. [DOI:10.18632/oncotarget.19384]
29. Chataway J, Sawcer S, Feakes R, et al. A screen of candidates from peaks of linkage: evidence for the involvement of myeloperoxidase in multiple sclerosis. J Neuroimmunol 1999; 98(2): 208-13. [DOI:10.1016/S0165-5728(99)00089-2]
30. Zakrzewska-Pniewska B, Styczynska M, Podlecka A, et al. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004; 10: 266-71. [DOI:10.1191/1352458504ms1015oa]
31. Zargari M, Allameh A, Sanati MH, et al. Relationship between the clinical scoring and demyelination in central nervous system with total antioxidant capacity of plasma during experimental autoimmune encephalomyelitis development in mice. Neurosci letters 2
32. Koch MW, Ramsaransing GS, Arutjunyan AV, et al. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 2006; 253(4): 483-7. [DOI:10.1007/s00415-005-0037-3]
33. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease?. Biochim Biophys Acta 2010; 1802(1): 66-79. [DOI:10.1016/j.bbadis.2009.07.002]
34. XiaoBG, Ma CG, Xu LY, et al.IL-12/IFN-γ/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. Mol Immunol 2008; 45: 1191-6. [DOI:10.1016/j.molimm.2007.07.003]
35. Bredt DS, Snyder SH. Nitric oxide, a novel neuronal messenger. Neuron 1992; 8(1):3 -11. [DOI:10.1016/0896-6273(92)90104-L]
36. Simmons ML, Murphy S. Induction of nitric oxide synthase in glial cells. J Neurochem 1992; 59(3): 897-905. [DOI:10.1111/j.1471-4159.1992.tb08328.x]
37. Kolb H, Kolb-Bachofen V. Nitric oxide: a pathogenetic factor in autoimmunity. Immunol Today. 1992; 13(5): 157-60. [DOI:10.1016/0167-5699(92)90118-Q]
38. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1(4): 232-41. [DOI:10.1016/S1474-4422(02)00102-3]
39. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 2011; 74(1): 1-13. [DOI:10.1111/j.1365-3083.2011.02536.x]
40. Cigremis Y, Jose M, Ozgurlu F, et al. The investigation of erythrocyte SOD, Cat and GPX antioxidant enzyme level in pateints with type 2 diabetes mellitus. G.U. J Sci 2003; 16(2): 239-44.
41. Palanduz S, Ademoglu E, Gokkusu C, et al. Plasma antioxidants and type 2 diabetes mellitus. Res Commun Mol Pathol Pharmacol 2001; 109(5-6): 309-18.
42. Al-Shebly MM, Mansour MA. Evaluation of Oxidative Stress and Antioxidant Status in Diabetic and Hypertensive Women during Labor. Oxid Med Cell Longev 2012; 2012: 1-6. [DOI:10.1155/2012/329743]
43. Aguirre L, Arias N, Macarulla MT, et al. Beneficial effects of quercetin on obesity and diabetes. Open Nutraceuticals J 2011; 4: 189-98. [DOI:10.2174/1876396001104010189]
44. Drulović J, Dujmović I, Stojsavljević N, et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol 2001; 248(2): 121-6. [DOI:10.1007/s004150170246]
45. Peng F, Zhang B, Zhong X, et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 2008; 14(2): 188-96. [DOI:10.1177/1352458507082143]
46. Muthian G, Bright JJ. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J Clin Immunol 2004; 24(5):542-52. [DOI:10.1023/B:JOCI.0000040925.55682.a5]

Send email to the article author

Rights and Permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | ISMJ

Designed & Developed by: Yektaweb